Efficacy and Safety Profile of CPX-351 in Secondary Acute Myeloid Leukemia (sAML): A Systematic Review

被引：0
|
作者：
Ibrahim, Ahmed [1 ]
Yousaf, Muhammad Abdullah [1 ]
Ikram, Mariam [2 ]
Khalid, Huma
Anum [3 ]
Safdar, Omar A. [4 ]
Anwer, Zain [5 ]
Faraz, Fatima [1 ]
Rehman, Mohammad [1 ]
Saad, Muhammad [2 ]
机构：
[1] Rawalpindi Med Univ, Rawalpindi, Pakistan
[2] Shifa Int Hosp Ltd, Islamabad, Pakistan
[3] Faisalabad Med Univ, Faisalabad, Pakistan
[4] Univ Arizona, Tucson, AZ USA
[5] Cleveland Clin, Cleveland, OH USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187301
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Real World Evidence of Efficacy of CPX-351 in Secondary Acute Myeloid Leukemia Defined According to Who 2022 Classification
    Riva, Carola
    Minetto, Paola
    Chies, Maria
    Uernarecci, Chiara
    Zecchetti, Giada
    Maio, Elena
    Azzanelli, Ylenia
    Colombo, Nicoletta
    Rosellini, Sara
    Parodi, Alessia
    Tedone, Elisabetta
    Carminati, Enrico
    Puglisi, Francesco
    Nurra, Clara
    Fugazza, Giuseppina
    Nozza, Paolo
    Cea, Michele
    Lemoli, Roberto Massimo
    Guolo, Fabio
    BLOOD, 2024, 144 : 1471 - 1472
  • [12] Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
    Chen, Evan C.
    Fathi, Amir T.
    Brunner, Andrew M.
    ONCOTARGETS AND THERAPY, 2018, 11 : 3425 - 3434
  • [13] CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia
    Assi, Rita
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias J.
    Gborogen, Rosilyn A.
    Chamoun, Kamal
    Wierda, William G.
    Borthakur, Gautam
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [14] CPX-351 Exposure-Response Analyses for Efficacy and Safety in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Wang, Qi
    Gosselin, Nathalie H.
    Absalon, Michael J.
    Kolb, E. Anders
    Marier, J. F.
    Alonzo, Todd A.
    Faderl, Stefan
    Cooper, Todd M.
    BLOOD, 2020, 136
  • [15] Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Alotaibi, Shaykhah
    Niederwieser, Dietger
    Ahmed, Syed Osman
    Sanz, Jaime
    Mohty, Mohamad
    Aljurf, Mahmoud
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : 575 - 580
  • [16] Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia
    Roboz, Gail J.
    Larson, Melissa L.
    Rubenstein, S. Eric
    Solomon, Scott R.
    Schiller, Gary J.
    An, Qi
    Chiarella, Michael
    Louie, Arthur C.
    Lin, Tara L.
    LEUKEMIA & LYMPHOMA, 2020, 61 (05) : 1188 - 1194
  • [17] CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia
    Lee, Dasom
    Jain, Akriti G.
    Deutsch, Yehuda
    Eatrides, Jennifer
    Chan, Onyee
    Padron, Eric
    Kuykendall, Andrew
    Komrokji, Rami
    Lancet, Jeffrey
    Sallman, David
    Talati, Chetasi
    Sweet, Kendra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (10): : 774 - 779
  • [18] CPX-351 Population Pharmacokinetics in Pediatric and Adult Patients with Acute Myeloid Leukemia (AML)
    Wang, Qi
    Cooper, Todd M.
    Absalon, Michael J.
    Kolb, E. Anders
    Vasilinin, Grygoriy
    Gosselin, Nathalie H.
    Alonzo, Todd A.
    Marier, J. F.
    BLOOD, 2020, 136
  • [19] CPX-351 ASSOCIATED RASH IN PEDIATRIC PATIENTS WITH ACUTE MYELOID LEUKEMIA: A CASE SERIES
    Weisnicht, Allison
    Chan, Audrey
    Stevens, Alexandra
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S56 - S56
  • [20] Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia
    Asghari, Hannah
    Lancet, Jeffrey
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1305 - 1312
12345